Please assess the completion status of the following clinical trial:

Trial Title: Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with secondary adrenal insufficiency.~* Age ≥ 18 - 75 years~* ≥ One year after tumor treatment with surgery and/or radiotherapy~* On stable concomitant medications for at least six months prior to entry of study~* Body weight 50-100 kg~Exclusion Criteria:~* Inability of legal consent~* Documented cognitive impairment~* Drug abuse/dependence~* History of / current psychiatric disorders~* Use of anti-epileptics (e.g. carbamezapine)~* Cushing Disease~* Type 1 diabetes or Type 2 diabetes with medication known to induce hypoglycemia (f.e. Sulfonylurea derivatives~* Current treatment for second malignancy~* Have a significant medical condition (e.g. hepatic, respiratory, or cardiovascular) which, in the opinion of the investigator, may interfere with the interpretation of results and safety or efficacy evaluations.~* A history of frequent hypocortisolism~* Hospitalization during study~* Work in shifts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- First low dose HC followed by high dose HC (Type: ACTIVE_COMPARATOR): First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
- First high dose HC followed by low dose HC (Type: ACTIVE_COMPARATOR): First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).